In a recent write up published online on the European Pharmaceutical Manufacturer, Sciformix CSO Dr. Chitra Lele identifies real-world evidence (RWE) as the key to briding the gap between clinical development and patient access.
RWE, she says, plays an important role in both pre- and post-approval in clinical development.
“In the clinical development stage, RWE can enhance the effectiveness of randomised clinical trials, for example in the initial phases it can aid in the identification of patient sub-populations and in understanding patient pathway, disease progress, treatment preferences and patient-related outcomes,” Lele writes.
Following approval, RWE can be used as a key tool in developing a safer, more effective treatment.
RWE can also open doors to treatment options otherwise unavailable by providing payers important data on real-world effectiveness and cost-effectiveness when held up to other drugs.
To read Lele’s full write up, click here.